GSBS Hosts COVID-19 Webinar
Watch this video to learn about the development of COVID-19 vaccines and treatments, what we are learning about the virus and have yet to learn, and how the pandemic has spotlighted the importance of the biomedical community. Dean Jay facilitated this informative discussion between Helen W. Boucher, MD, FACP, FIDSA, Marta Gaglia, PhD, and Michael Rosenblatt, MD.
Helen Boucher leads the Tufts and Wellforce Infectious Diseases COVID-19 response and has been active in college and K–12 school reopening and testing plans. She is chief of the Division of Geographic Medicine and Infectious Diseases and director of the Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance at Tufts.
Marta Gaglia is assistant professor of molecular biology and microbiology at Tufts University School of Medicine. Her laboratory studies how viruses block innate immune responses to infection and is currently investigating the function of SARS-CoV-2 components in this process.
Michael Rosenblatt is chief medical officer of Flagship Pioneering, the venture firm that created Moderna. He serves on Moderna’s Vaccine Acceleration Committee and is a consultant to Moderna. He is also engaged in other Flagship companies that work on generating anti-virals and antibodies to/diagnostics for SARS-CoV-2.